GKOS
Glaukos Corp
NYSE: GKOS · HEALTHCARE · MEDICAL DEVICES
$135.37
+2.72% today
Updated 2026-06-05
Market cap
$7.45B
P/E ratio
—
P/S ratio
13.51x
EPS (TTM)
$-3.30
Dividend yield
—
52W range
$73 – $148
Volume
1.0M
Glaukos Corp (GKOS) Financial Forecast & Price Target 2030
Research-backed projections from analyst consensus, management guidance, and sector analysis.
Research-backed GKOS price target 2030 projection accounting for share dilution, balance sheet debt, and time value of money.
Current price
$135.37
Today
Analyst consensus
$146.17
+7.98% · 12M
2030 Base
$158.99
+17.45% future
NPV today
$103.76
@ 10% WACC
14 analysts:
11 Buy1 Hold1 Sell
Management guidance
Management raised 2026 revenue guidance to $620M–$635M (midpoint $627.5M), representing 23.6% growth from 2025's $507.4M. CEO commentary emphasized strong momentum in iDose TR (repeat-dosing label approved Jan 2026) and Epioxa (permanent J-code effective July 1, 2026), with both products expected to drive sustained high-20s to mid-30s growth through 2027–2028. No explicit guidance beyond 2026, but company signaled confidence in 'deep pipeline' and 'path to cash-flow breakeven,' implying multi-year revenue acceleration.
Sources: Management guidance, analyst consensus, sector analysishigh confidence
GKOS · Glaukos Corp · Revenue & price projection · 2023–2030E
Actual / 2030 target Projected revenue Base case price Bull to bear range
Bear case (2030)
$84.34
NPV today: $55.04
Base case (2030)
$158.99
NPV today: $103.76
Bull case (2030)
$358.07
NPV today: $233.68
WallStSmart.com
GKOS financial forecast · Research-backed projections
| Metric | 2025 | 2026 (E) | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) ★ |
|---|---|---|---|---|---|---|
| Revenue | $0.5B | $0.7B | $0.9B | $1.1B | $1.3B | $1.5B |
| Revenue growth | 32.3% | 23.6% | 29.3% | 24.0% | 20.8% | 20.0% |
| Net margin | — | -2.1% | 3.6% | 7.3% | 9.7% | 11.9% |
| EPS | $-1.52 | $-0.25 | $0.55 | $1.35 | $2.10 | $2.95 |
| Diluted shares | — | 59M | 59M | 60M | 60M | 60M |
| Net debt | — | $116.63M | $266.58M | $449.85M | $666.45M | $916.37M |
| P/S multiple | — | 7.0x | 7.0x | 7.0x | 7.0x | 7.0x |
| Implied price (base) | — | $80.96 | $101.50 | $121.37 | $140.47 | $158.99 |
★ 2030E is the model's terminal target year. Implied price = (Revenue × P/S − Net debt) ÷ Diluted shares.
Scenario detail · Three drivers, three outcomes
| 2030E driver | Bear | Base | Bull |
|---|---|---|---|
| Revenue | $1.5B | $1.5B | $1.5B |
| P/S multiple | 4.0x | 7.0x | 15.0x |
| Diluted shares | 60M | 60M | 60M |
| Net debt | $916.37M | $916.37M | $916.37M |
| Implied P/E † | 29x | 54x | 121x |
| 2030 Price | $84.34 | $158.99 | $358.07 |
| NPV @ 10% | $55.04 | $103.76 | $233.68 |
† Implied P/E: Multiples remain elevated across all three scenarios because GKOS is valued primarily on revenue scale during its growth phase, not near-term earnings power. Lower P/E in the bear case reflects multiple compression, but the absolute level stays high since 2030E still represents a hypergrowth-to-mature transition year.
EV to per-share bridge · How we get to $158.99 base case
GKOS catalysts and risks
Growth catalysts
+ iDose TR repeat-dosing label driving incremental procedures; installed base expanding across US ophthalmic centers
+ Epioxa J-code reimbursement effective July 1, 2026; addresses keratoconus market (~50k-75k procedures/year in US alone)
+ Continued geographic expansion of glaucoma franchise (iStent inject) into international markets (EU, APAC); established US dominance provides platform for adjacent indications
+ Potential label expansions or combination therapy approvals for iDose TR in 2027–2028
+ Achievement of gross margin expansion through manufacturing scale and mix shift toward higher-margin Epioxa
Key risks
- Payer adoption delays for Epioxa despite J-code; complex reimbursement environment for corneal therapeutics
- Competition from Bausch + Lomb (refractive surgery) and emerging DMEK alternatives in keratoconus
- Continued net losses ($189M TTM) and negative operating margins (-15.6%); path to profitability depends on revenue growth acceleration without proportional cost increase
- Insider selling trend (CFO $1.4M, COO $2.8M, director $703k in May 2026); suggests stock may be fairly/fully valued near-term despite growth narrative
- iDose TR uptake dependent on surgeon training and reimbursement; early sales data shows 41% YoY Q1 growth but durability beyond 2027 uncertain
Methodology · Glaukos Corp 2030 stock forecast model
Glaukos Corp 2030 price target is calculated using WallStSmart's research model. Revenue projections are derived from analyst consensus across 14 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts. The model is built on five core components:
| 1. Share dilution | Projected from per-ticker schedule of SBC + equity raise activity, compounding year by year (3% cumulative for GKOS by 2030) |
| 2. Net debt | EV minus net debt yields equity value; debt projected from capex cycle trajectory ($916.37M by 2030) |
| 3. Time value | NPV calculated using 10% WACC (CAPM: beta 0.948) |
| 4. Multiple framework | P/S compresses with scale: bear 4.0x / base 7.0x / bull 15.0x |
| 5. Scenario design | Bull/Base/Bear vary revenue, margin, shares, debt, and multiple independently |
WallStSmart research model · Not financial advice · Past performance is not indicative of future results · Last researched: May 21, 2026.
GKOS price target FAQ
What is the GKOS price target for 2030?
WallStSmart's Glaukos Corp 2030 base case is $158.99 per share, with a bull case of $358.07 and bear case of $84.34. The NPV of the base case discounted to today at 10% WACC is $103.76.
How is the Glaukos Corp 2030 stock forecast calculated?
The GKOS 2030 projection multiplies projected revenue by a growth-adjusted P/S multiple to derive enterprise value, subtracts projected net debt to get equity value, then divides by diluted shares outstanding accounting for dilution from stock-based compensation and equity raises.
Why does the GKOS price target account for dilution?
Glaukos Corp is projected to grow diluted share count from 59M to 60M by 2030 (a 3% increase) through stock-based compensation and capital raises. Ignoring this would inflate the price target by approximately 3%.
What is the analyst consensus on GKOS stock?
14 analysts cover GKOS with an average 12-month price target of $146.17. The 2030 projection extends this framework with longer-horizon assumptions including dilution and time value of money.